The Prognostic Value of miR-302b in Patients With NSCLC

Abstract Background: Lung cancer is the most common cancer worldwide. The most frequent type of lung cancer is non-small cell lung cancer (NSCLC). MicroRNAs (miRNAs) have been reported to play important role in human cancers. Studies suggest that the aberrant expression of miRNAs could act as the diagnostic or prognostic biomarker in human cancers, including lung cancer. MicroRNA-302b (miR-302b) has ever been investigated in several human cancers. The aim of this study was to examine the prognostic value of miR-302b in patients with NSCLC.Methods: Quantitative real-time RT-PCR (qRT-PCR) analysis were used to measure the expression level of miR-302b in NSCLC and adjacent noncancerous samples. The relationship of miR-302b with the clinicopathological data of NSCLC was analyzed by Chi-square test. The prognostic value of miR-302b was assessed by using the Kaplan-Meier survival curves and Cox regression analysis.Results: The expression level of miR-302b was downregulated in the NSCLC samples compared with the paired adjacent noncancerous samples (P < 0.05). The decreased miR-302b was found correlated with the differentiation (P = 0.019) and lymph node metastasis (P = 0.019) of NSCLC. The survival curves suggested that patients with lower miR-302b expression had poor overall survival than those with high miR-302b expression. The results of Cox analysis demonstrated that the expression of miR-302b was an independent and effective prognostic factor in NSCLC patients with the P of 0.002 (HR = 2.508, 95% CI = 1.410 - 4.463).Conclusion: In one word, the expression of miR-302b was decreased in NSCLC samples, and the miR-302 expression might act as a prognostic biomarker in NSCLC patients.